WO2000012049A3 - A method for the treatment of staphylococcal disease - Google Patents

A method for the treatment of staphylococcal disease Download PDF

Info

Publication number
WO2000012049A3
WO2000012049A3 PCT/US1999/020396 US9920396W WO0012049A3 WO 2000012049 A3 WO2000012049 A3 WO 2000012049A3 US 9920396 W US9920396 W US 9920396W WO 0012049 A3 WO0012049 A3 WO 0012049A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
lysostaphin
staphylococcal
staphylococcal disease
effective
Prior art date
Application number
PCT/US1999/020396
Other languages
French (fr)
Other versions
WO2000012049A2 (en
Inventor
Michael M Climo
Gordon L Archer
Beth P Goldstein
Original Assignee
Ambi Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambi Inc filed Critical Ambi Inc
Priority to AU58111/99A priority Critical patent/AU5811199A/en
Priority to DE69943089T priority patent/DE69943089D1/en
Priority to IL14164899A priority patent/IL141648A0/en
Priority to AT99945525T priority patent/ATE493145T1/en
Priority to EP99945525A priority patent/EP1107722B1/en
Priority to JP2000567170A priority patent/JP2002523437A/en
Priority to CA002341699A priority patent/CA2341699A1/en
Publication of WO2000012049A2 publication Critical patent/WO2000012049A2/en
Publication of WO2000012049A3 publication Critical patent/WO2000012049A3/en
Priority to NO20010953A priority patent/NO20010953L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24075—Lysostaphin (3.4.24.75)

Abstract

Lysostaphin is an effective antibiotic in the treatment of staphylococcal infection. Large doses of lysostaphin or lysostaphin analogues are effective in short course, or even one dose administration, in treating and eradicating staphylococcal infections, including those resistant to conventional antibiotics.
PCT/US1999/020396 1998-08-27 1999-08-27 A method for the treatment of staphylococcal disease WO2000012049A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU58111/99A AU5811199A (en) 1998-08-27 1999-08-27 A method for the treatment of staphylococcal disease
DE69943089T DE69943089D1 (en) 1998-08-27 1999-08-27 METHOD FOR THE TREATMENT OF STAPHYLOKOCKSINFECTIONS
IL14164899A IL141648A0 (en) 1998-08-27 1999-08-27 A method for the treatment of staphylococcal disease
AT99945525T ATE493145T1 (en) 1998-08-27 1999-08-27 METHOD OF TREATING STAPHYLOCOCCAL INFECTIONS
EP99945525A EP1107722B1 (en) 1998-08-27 1999-08-27 A method for the treatment of staphylococcal infection
JP2000567170A JP2002523437A (en) 1998-08-27 1999-08-27 Methods for treating staphylococcal diseases
CA002341699A CA2341699A1 (en) 1998-08-27 1999-08-27 A method for the treatment of staphylococcal disease
NO20010953A NO20010953L (en) 1998-08-27 2001-02-26 A method for the treatment of staphylococcal disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/140,732 US6028051A (en) 1997-07-23 1998-08-27 Method for the treatment of staphylococcal disease
US09/140,732 1998-08-27

Publications (2)

Publication Number Publication Date
WO2000012049A2 WO2000012049A2 (en) 2000-03-09
WO2000012049A3 true WO2000012049A3 (en) 2000-05-25

Family

ID=22492556

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/020396 WO2000012049A2 (en) 1998-08-27 1999-08-27 A method for the treatment of staphylococcal disease

Country Status (12)

Country Link
US (1) US6028051A (en)
EP (1) EP1107722B1 (en)
JP (1) JP2002523437A (en)
AR (1) AR023645A1 (en)
AT (1) ATE493145T1 (en)
AU (1) AU5811199A (en)
CA (1) CA2341699A1 (en)
DE (1) DE69943089D1 (en)
IL (1) IL141648A0 (en)
NO (1) NO20010953L (en)
WO (1) WO2000012049A2 (en)
ZA (1) ZA995444B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875903B2 (en) * 1998-06-22 2005-04-05 University Of Vermont Treatment of Staphylococcus infections
US7091332B1 (en) 1998-06-22 2006-08-15 University Of Vermont Treatment of staphylococcus infections
US6569830B1 (en) 1999-03-05 2003-05-27 Ambi, Inc. Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains
US20030211995A1 (en) * 2001-12-21 2003-11-13 Kokai-Kun John Fitzgerald Methods and formulations for eradicating or alleviating staphylococcal nasal colonization using lysostaphin
JP4348194B2 (en) * 2001-12-21 2009-10-21 バイオシネクサス インコーポレーテッド A truncated lysostaphin molecule with enhanced staphylococcal lytic activity
US6759881B2 (en) * 2002-03-22 2004-07-06 Rambus Inc. System with phase jumping locked loop circuit
BR0308710A (en) * 2002-03-26 2007-01-09 Biosynexus Inc antimicrobial polymer conjugates
BR0308285A (en) * 2002-03-26 2005-04-12 Biosynexus Inc Bacterial biofilm disruption by enzymes
JP2006514944A (en) * 2002-12-10 2006-05-18 バイオシネクサス インコーポレーテッド Anti-infective preparation for topical use
US20100221237A1 (en) * 2003-03-26 2010-09-02 Biosynexus Incorporated Enzyme disruption of bacterial biofilms
WO2007041621A2 (en) * 2005-10-03 2007-04-12 Xingsheng Sean Ling Hybridization assisted nanopore sequencing
WO2008105826A2 (en) * 2006-09-05 2008-09-04 Biosynexus Incorporated Compositions compromising lysostaphin variants and methods of using the same
US20110044968A1 (en) * 2008-03-10 2011-02-24 Pharmal N Corporation Compositions for treatment with metallopeptidases, methods of making and using the same
WO2009150171A1 (en) * 2008-06-10 2009-12-17 Profos Ag Method of treatment of inflammatory diseases
CN106795506B (en) * 2014-05-14 2020-11-27 达特茅斯学院理事会 Deimmunized lysostaphin and methods of use
EP3485899A4 (en) 2017-09-25 2020-05-20 Georgy Georgievich Chumburidze Thermostable composition with antiviral and antibacterial activity and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3067099A (en) * 1955-09-16 1962-12-04 Lilly Co Eli Vancomycin and method for its preparation
US4980163A (en) * 1989-03-01 1990-12-25 Public Health Research Institute Of The City Of New York Novel bacteriocin compositions for use as enhanced broad range bactericides and methods of preventing and treating microbial infection

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931390A (en) * 1986-04-16 1990-06-05 Public Health Research Institute Of The City Of New York, Inc. Expression of the cloned lysostaphin gene
US5858962A (en) * 1987-05-11 1999-01-12 Ambi Inc. Composition for treating mastitis and other staphylococcal infections
US5342612A (en) * 1991-12-20 1994-08-30 American Cyanamid Company Compositions for the treatment of mammalian diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3067099A (en) * 1955-09-16 1962-12-04 Lilly Co Eli Vancomycin and method for its preparation
US4980163A (en) * 1989-03-01 1990-12-25 Public Health Research Institute Of The City Of New York Novel bacteriocin compositions for use as enhanced broad range bactericides and methods of preventing and treating microbial infection

Also Published As

Publication number Publication date
EP1107722A4 (en) 2006-05-17
US6028051A (en) 2000-02-22
NO20010953D0 (en) 2001-02-26
NO20010953L (en) 2001-03-21
DE69943089D1 (en) 2011-02-10
IL141648A0 (en) 2002-03-10
WO2000012049A2 (en) 2000-03-09
ATE493145T1 (en) 2011-01-15
AU5811199A (en) 2000-03-21
AR023645A1 (en) 2002-09-04
CA2341699A1 (en) 2000-03-09
ZA995444B (en) 2000-07-10
JP2002523437A (en) 2002-07-30
EP1107722A2 (en) 2001-06-20
EP1107722B1 (en) 2010-12-29

Similar Documents

Publication Publication Date Title
WO2000012049A3 (en) A method for the treatment of staphylococcal disease
BR9510423A (en) Low rigidity multilamellar liposomal formulation The process of treating or prophylaxis a bacterial infection in an animal and a mucoid variant thereof, using the antibacterial liposomal formulation
WO2002056912A3 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
EP1576963A3 (en) Use of botulinum toxin in the treatment of pain due to an infection
CA2189658A1 (en) Controlled-Release Dosage Forms of Azithromycin
EP1273298A3 (en) Ritonavir in combination with an additional HIV protease inhibitor for treating aids
WO2000061115A3 (en) Pharmaceutical formulation comprising amoxycillin
WO2002007759A3 (en) Clostridial toxin derivatives and methods for treating pain
NO954996L (en) Use of nona and decapeptides for the manufacture of a medicament for the treatment of AIDS
CA2366304A1 (en) Novel method of treatment
ZA986593B (en) A method for the treatment of staphylococcal disease
BR9405737A (en) Compound process of inhibiting HIV transcriptase, process for preventing HIV infection or treating HIV infection, pharmaceutical composition useful for inhibiting HIV transcriptase, and useful for preventing or treating HIV infection or for the treatment of AIDS or ARC
WO1999063978A3 (en) Methods of treating microbial infection and therapeutic formulations therefor
WO1999009964A3 (en) Pharmaceutical composition containing clindamycin and clotrimazol for treating vaginal infections
BR9708930A (en) Compound derived from 3-decladinose-2,3-anhydro erythromycin or a pharmaceutically acceptable salt or ester thereof Process for the preparation of the compound Pharmaceutical composition and process for treating bacterial infections
ATE259654T1 (en) PHARMACEUTICAL PREPARATIONS FOR THE CONTROL OR PROPHYLAXIS OF SURFACES INFECTED BY MICROORGANISMS
WO2003059246A3 (en) Methods of using conjugates of saccharides and acetamidino or guanidino compounds for treating bacterial infections
IE831920L (en) 2,4-diamino-5-piperazinyl pyrimidines
WO2000030435A3 (en) Foulbrood treatments
DE69813200D1 (en) IMPROVING Wounds Healing With CM101 / GBS-TOXIN
ES2104223T3 (en) 2 - ((2- (N-ISOBUTYL-N-METHYL) AMINO) -BENCILSULFINIL) BENZMIDAZOLE AS ANTIMICROBIAL AGENT AGAINST HELICOBACTER PYLORI.
AU5848690A (en) Preparation for topical treatment of infections caused by virus, bacteria and fungi
EA200100010A1 (en) LOCAL APPLICATION OF OXAZOLIDINONES FOR TRANSDERMAL DELIVERY
AU2396900A (en) Treatment and prevention of hiv and other viral infections
WO1998034598A3 (en) Homogeneous granulated formulations for dose sipping technology

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2341699

Country of ref document: CA

Ref country code: CA

Ref document number: 2341699

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 141648

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 510270

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1999945525

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 58111/99

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1999945525

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642